<DOC>
	<DOCNO>NCT00841438</DOCNO>
	<brief_summary>The ADMIRAL ( Platelet glycoprotein IIb/IIIa inhibition coronary stenting acute myocardial infarction ) study demonstrate early administration abciximab patient ST elevation acute myocardial infarction prior PCI improve clinical outcome specifically design randomize study address issue early upstream use GP IIb/IIIa inhibitor ST elevation acute myocardial infarction undergo PCI , especially era routine pretreatment 600 mg clopidogrel . Therefore , objective randomize ECLAT-STEMI study ass hypothesis early upstream use Clotinab useful therapy patient ST elevation MI undergo PCI compare `` provisional use '' , even pretreatment 600-mg loading dose clopidogrel .</brief_summary>
	<brief_title>Efficacy Early Administration Clotinab Acute Myocardial Infarction</brief_title>
	<detailed_description>It well know platelet-mediated thrombosis account pathophysiology acute coronary syndrome ( ACS ) ( 1,2 ) . In treatment ACS , intravenous platelet glycoprotein ( GP ) IIb/IIIa receptor antagonist platelet aggregation may reduce risk ischemic complication ( 3-7 ) . Therefore , management ACS , Platelet GP IIb/IIIa receptor inhibitor develop promise new therapy reduction coronary event improvement clinical outcome . Abciximab , one platelet GP IIb/IIIa receptor blocker , develop Coller 1985 name 7E3 ( 8 ) . Abciximab chimeric human monoclonal antibody bind platelet surface GP IIb/IIIa receptor competitively adhesive molecule fibrinogen von Willebrand factor , block final stage platelet aggregation ( 9 ) . The effect Abciximab prove many clinical trial EPIC trial ( 9 ) , EPILOG trial ( 10 ) , TARGET ( 11 ) etc . The contribution GP IIb/IIIa inhibition ACS ( Tirofiban ) show placebo-controlled trial upstream GP IIb/IIIa inhibition initiate upon admission ( 12,13 ) . Although result encourage , data support use upstream GP IIb/IIIa inhibitor . Moreover , accord GUSTO-IV trial ( 14 ) , use Abciximab recommend manner upstream use . To evaluate role abciximab conservatively treat non-ST-elevation ACS patient , GUSTO-IV study randomize 7800 patient non-ST-elevation ACS receive either placebo Abciximab bolus ( 0.25 mg/kg ) 24-hour 48-hour infusion ( 0.125 µg/kg/min ) . However , fact , trend note potential harm high abciximab dose . Even subgroup analysis include high-risk troponin-positive patient show benefit either abciximab regimen ( 9.7 % placebo , 10.2 % 24-hour abciximab , 11.7 % 48-hour abciximab death MI 30 day , P = NS ) . Because result , majority patient receive abciximab relatively late , time PCI clinical practice . However , ADMIRAL study ( 3 ) demonstrate early administration abciximab patient ST elevation acute myocardial infarction prior PCI improve clinical outcome also specifically design randomize study address issue early upstream use GP IIb/IIIa inhibitor ST elevation acute myocardial infarction undergo PCI , especially era routine pretreatment 600 mg clopidogrel . Therefore , objective randomize ECLAT-STEMI study ass hypothesis early upstream use Clotinab useful therapy patient ST elevation MI undergo PCI compare `` provisional use '' , even pretreatment 600-mg loading dose clopidogrel . The Clotinab , product make ISU ABXIS CO. , LTD , produce insert anti- platelet GP IIb/IIIa DNA Chinese hamster 's ovary cell . Since contains identical active ingredient ReoPro® domestic market , expect Clotinab efficacy ReoPro® platelet GP IIb/IIIa receptor inhibitor . Recently , Clotinab show safe effective prevent ischemic heart complication high-risk patient undergo PCI . 2 . Study Protocol 2-1 . Objectives : Randomized , control , single blind , multi-center trial To assess hypothesis early upstream use Clotinab useful therapy patient ST elevation myocardial infarction undergo PCI compare `` provisional use '' , even pretreatment 600-mg loading dose clopidogrel . 2-2 . Study Design : Efficacy CLotinab ST-elevation Acute myocardial infarction Trial - ST Elevation Myocardial Infarction ( The ECLAT - STEMI study ) 2-3 . Study Endpoints : 1 . Primary Endpoint : Efficacy To evaluate effect early upstream use Clotinab ( start emergency room ) co-administered clopidogrel load dose 600mg STEMI - 30 Days MACCE ( death , MI , TVR , cerebrovascular event ) 2 . Secondary Endpoint : Efficacy Safety To evaluate safety early upstream use Clotinab ( start emergency room ) co-administered clopidogrel load dose 600mg STEMI - TIMI flow PCI - Corrected TIMI frame count PCI - Procedural success ( No reflow incidence ) - MACCE 9 month - Major bleed event ( According TIMI criterion ) - 9 month Angiography Finding</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1 . The patient must least 1880 year age . 2 . The patient symptom acute myocardial infarction within 12 hour ST segment elevation 1 mm least two contiguous lead EKG new onset LBBB . 3 . The patient guardian agrees study protocol provide informed , write consent . 1 . Patients PCI undergone within 12 hour receive study drug 2 . Cardiogenic shock symptomatic hypotension sit SBP &lt; 95 mmHg 3 . The history major surgery , trauma , retinal hemorrhage , significant gastrointestinal genitourinary bleeding within recent 6 week ; 4 . History cerebrovascular attack within two year , cerebrovascular attack significant residual neurological deficit 5 . Severe malignant hypertension ( = sit SBP &gt; 180 mmHg and/or sit DBP &gt; 105 mmHg ) 6 . The patient require oral anticoagulant trial ; patient administrate oral anticoagulant within 7 day 7 . The history diagnosis vasculitis ; renal insufficiency ( level serum creatinine two time higher upper limit normal center ) 8 . The patient could take antiplatelet drug 9 . The patient might die disease cardiac disease trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Angioplasty</keyword>
	<keyword>Transluminal</keyword>
	<keyword>Percutaneous Coronary</keyword>
</DOC>